<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="24910">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01710514</url>
  </required_header>
  <id_info>
    <org_study_id>000072</org_study_id>
    <nct_id>NCT01710514</nct_id>
  </id_info>
  <brief_title>A Phase III Study of FE 999913 in Japanese Female Patients Undergoing Fertility Treatment</brief_title>
  <official_title>A Multi-Center, Randomized, Open-Label, Parallel Group Study of FE 999913 Vaginal Tablet 100 mg in Japanese Female Patients Undergoing Fertility Treatment [In Vitro Fertilization/Embryo Transfer (IVF-ET)]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of the study are to verify sufficient supplementation of luteal hormone after
      administrating FE999913 Vaginal Tablet BID or TID and to determine the efficacy and safety
      of FE999913 Vaginal Tablet in Japanese women undergoing fertility treatment with IVF-ET (a
      fresh embryo transfer).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The proportion of subjects with blood progesterone concentration not less than 10 ng/mL</measure>
    <time_frame>Day 5 of treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Ongoing pregnancy rate</measure>
    <time_frame>Week 5 of study</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Positive βeta Human Chorionic Gonadotrophin (βhCG)</measure>
    <time_frame>Week 2 of study</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Pregnancy Rate</measure>
    <time_frame>Week 4 of study</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Progesterone Concentration</measure>
    <time_frame>Weeks 2, 4, 5, 8, and 10 of study</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and Severity of Adverse Events</measure>
    <time_frame>During 10 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory Tests (Biochemistry, Hematology, and Urinalysis)</measure>
    <time_frame>At early follicular phase of the menstrual cycle (day 2-4) and week 10</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-lead Electrocardiogram (ECG)</measure>
    <time_frame>At early follicular phase of the menstrual cycle (day 2-4) and week 10</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examination of body height, weight and BMI</measure>
    <time_frame>At early follicular phase of the menstrual cycle (day 2-4) and week 10</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gynecological examination of pelvis and breast</measure>
    <time_frame>At early follicular phase of the menstrual cycle (day 2-4) and week 10</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>A standard physical and gynecological examination will be performed including assessments of the external genital organs, vagina, cervix, uterus and ovary.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">108</enrollment>
  <condition>Luteal Hormone Supplementation</condition>
  <arm_group>
    <arm_group_label>FE 999913 100 mg BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FE 999913 100 mg vaginal tablet BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FE 999913 100 mg TID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>FE 999913 100 mg vaginal tablet TID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FE 999913 vaginal tablet</intervention_name>
    <arm_group_label>FE 999913 100 mg BID</arm_group_label>
    <arm_group_label>FE 999913 100 mg TID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pre-menopausal adult women between the ages of 20 and 42 years.

          -  Early follicular phase (day 2-4) FSH ≤12 IU/L and Estradiol &lt;100 pg/mL.

          -  LH, prolactin (PRL), and thyroid-stimulating hormone (TSH), within the normal limits
             for the clinical laboratory tests, or considered not clinically significant by the
             investigator within 6 months prior to screening.

          -  Documented history of infertility [e.g., unable to conceive for at least one year (or
             for 6 months for women ≥38 years of age) or bilateral tubal occlusion or absence].

          -  Transvaginal ultrasound at screening (or within 14 days prior to screening)
             consistent with findings adequate for Assisted Reproduction Technology (ART) with
             respect to uterus and adnexa (peripheral reproductive organs).

          -  At least one cycle with no fertility medication prior to screening.

          -  Hysterosalpingography, hysteroscopy, sonohysterogram, or transvaginal ultrasound
             documenting a normal uterine cavity.

          -  Consent to contraception during the cycle in which pituitary down regulation is
             performed (long GnRH agonist protocol; prior to administration of GnRH agonist).

          -  Signed informed consent to fertility treatment using FE999913 Vaginal Tablet after
             the subject and her husband have thoroughly understood the content.

        Exclusion Criteria:

          -  Donor oocyte or embryo recipient; gestational or surrogate carrier.

          -  Undergoing blastomer biopsy and other experimental ART procedures.

          -  Severe hepatic dysfunction or disease.

          -  Active arterial or venous thromboembolism or severe thrombophlebitis, or a history of
             these events.

          -  Porphyria.

          -  Presence of any clinically relevant systemic disease (eg, insulin-dependent diabetes
             mellitus).

          -  Past or current surgical or medical condition which in the judgment of the Principal
             Investigator (or Sub-investigator) may interfere with absorption, distribution,
             metabolism, or excretion of the study drug.

          -  Subjects with a body mass index (BMI) of &gt;34 at time of Screening.

          -  Previous IVF or ART failure due to a poor response to gonadotropins*.

             * Defined as development of ≤2 mature follicles or history of 2 previous cycle
             cancellations prior to oocyte retrieval due to poor response.

          -  Presence of abnormal uterine bleeding of undetermined origin.

          -  Current or recent (within the past 12 months) substance abuse, including alcohol.

          -  Known or suspected breast or genital tract cancer.

          -  History of chemotherapy or radiotherapy for malignant disorder (chorionic disease).

          -  Currently breast feeding, pregnant or contraindication to pregnancy.

          -  Refusal or inability to comply with the requirements of the Protocol for any reason,
             including scheduled visits and clinical laboratory tests.

          -  Documented intolerance or allergy to any of the medications to be used in the study
             including the investigational medicinal product.

          -  Participation in any experimental drug study within 60 days prior to Screening.

          -  Use of any of the following medications during the pretreatment and treatment phase:
             hormonal drug products (use of oral contraceptives during down regulation is
             allowed), other progesterone drug products, hydrocortisone and other steroid drug
             products, and fertility modifiers such as insulin sensitizers.

          -  History of recurrent pregnancy loss defined as 3 or more spontaneous miscarriages.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Development Support</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hanabusa Women's Clinic</name>
      <address>
        <city>Kobe</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ebina Ladies Clinic</name>
      <address>
        <city>Ebina</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sophia Ladies Clinic</name>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bashamichi Ladies Clinic</name>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IVF Namba Clinic</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanno Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 29, 2013</lastchanged_date>
  <firstreceived_date>October 9, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
